Background: A model was built that characterized effects of individual factors on five-year prostate cancer (PCa) risk in the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial (PLCO) and the Selenium and Vitamin E Cancer Prevention Trial (SELECT). This model was validated in a third San Antonio Biomarkers of Risk (SABOR) screening cohort.
Methods: A prediction model for 1- to 5-year risk of developing PCa and Gleason > 7 PCa (HG PCa) was built on PLCO and SELECT using the Cox proportional hazards model adjusting for patient baseline characteristics. Random forests and neural networks were compared to Cox proportional hazard survival models, using the trial datasets for model building and the SABOR cohort for model evaluation. The most accurate prediction model is included in an online calculator.
Results: The respective rates of PCa were 8.9%, 7.2%, and 11.1% in PLCO (n = 31,495), SELECT (n = 35,507), and SABOR (n = 1790) over median follow-up of 11.7, 8.1 and 9.0 years. The Cox model showed higher prostate-specific antigen (PSA), BMI and age, and African American race to be associated with PCa and HGPCa. Five-year risk predictions from the combined SELECT and PLCO model effectively discriminated risk in the SABOR cohort with C-index 0.76 (95% CI [0.72, 0.79]) for PCa, and 0.74 (95% CI [0.65,0.83]) for HGPCa.
Conclusions: A 1- to 5-year PCa risk prediction model developed from PLCO and SELECT was validated with SABOR and implemented online. This model can individualize and inform shared screening decisions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966358 | PMC |
| http://dx.doi.org/10.1186/s12894-022-00986-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prospective evaluation of lung cancer screening eligibility criteria and lung cancer detection in the Yorkshire Lung Screening Trial.
J Thorac Oncol
December 2024
Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. Electronic address:
Introduction: Low dose CT (LDCT) screening for lung cancer reduces lung cancer mortality, but there is a lack of international consensus regarding the optimal eligibility criteria for screening. The Yorkshire Lung Screening Trial (YLST) was designed to evaluate lung cancer screening (LCS) implementation and a primary objective was prospective evaluation of 3 pre-defined eligibility criteria.
Methods: Individuals who had ever smoked, aged 55-80yrs, who responded to written invitation, underwent telephone risk assessment and if eligible by at least one criteria (PLCO≥1.
Dietary Pattern, Sputum DNA Methylation, and Lung Health: An Epidemiological Study in People Who Ever Smoked.
Chest
November 2024
Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM; Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM; Lung Cancer Program, Lovelace Biomedical Research Institute, Albuquerque, NM. Electronic address:
Background: We previously identified a panel of sputum DNA methylation that predicts lung aging and risk for lung cancer.
Research Question: Can the sputum methylation panel be used as a readout to derive a dietary pattern beneficial for lung health? Is this dietary pattern associated with various subjective and objective lung health phenotypes? Does this relationship vary among people who currently smoke (current smokers) vs previously smoked (former smokers)?
Study Design And Methods: Using the Lovelace Smoker Cohort (LSC), we employed the LASSO (least absolute shrinkage and selection operator) regularized Poisson regression to define a dietary pattern for sputum. Associations of the dietary pattern with objective and subjective lung health measurements were examined using generalized linear and Cox models in the LSC and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial.
5-Hydroxymethylated Biomarkers in Cell-Free DNA Predict Occult Colorectal Cancer up to 36 Months Before Diagnosis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
JCO Precis Oncol
October 2024
Department of Medicine, The University of Chicago, Chicago, IL.
Article Synopsis
- The study identified potential biomarkers in cell-free DNA (cfDNA) marked by 5-hydroxymethylcytosine (5hmC) that can detect colorectal cancer (CRC) up to 36 months prior to clinical diagnosis using samples from the PLCO Cancer Screening Trial.
- Research utilized 5hmC-seal assays and machine learning on cfDNA from 201 CRC cases and 401 controls, producing a predictive detection model with promising accuracy (AUC values around 77% in training and 73% in validation sets), outperforming traditional risk factor assessments.
- The 5hmC biomarkers hold potential for a minimally invasive test to enhance early CRC detection, thereby improving patient
Biomarker trajectory for earlier detection of lung cancer.
EBioMedicine
October 2024
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
Background: To determine whether an algorithm based on repeated measurements of a panel of four circulating protein biomarkers (4 MP) for lung cancer risk assessment results in improved performance over a single time measurement.
Methods: We conducted data analysis of the 4 MP consisting of the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fragment in pre-diagnostic sera from 2483 ever-smoker participants (389 cases and 2094 randomly selected non-cases) in the Prostate, Lung, Colorectal, Ovarian (PLCO) Study who had at least two sequential blood collections over 6 years. A parametric empirical Bayes (PEB) algorithm, which incorporates participant biomarker history at each time point, was compared to a single-threshold (ST) method.
Evaluation of risk prediction models to select lung cancer screening participants in Europe: a prospective cohort consortium analysis.
Lancet Digit Health
September 2024
Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France. Electronic address:
Background: Lung cancer risk prediction models might efficiently identify individuals who should be offered lung cancer screening. However, their performance has not been comprehensively evaluated in Europe. We aimed to externally validate and evaluate the performance of several risk prediction models that predict lung cancer incidence or mortality in prospective European cohorts.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!